Literature DB >> 2486154

Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment.

P Santavuori1, H Heiskala, T Autti, E Johansson, T Westermarck.   

Abstract

Juvenile neuronal ceroid-lipofuscinosis (JNCL) is a progressive encephalopathy characterized by a neural and extraneural accumulation of ceroid and lipofuscin like storage cytosomes and by an autosomal recessive inheritance. It begins with a gradual loss of vision at the age of 4-7 years and is accompanied by epilepsy, a loss of motor function, and a progressive dementia (Santavuori 1988). We have studied 26 Finnish JNCL patients treated with vitamins E, B2, B6 and sodium selenite (antioxidant treatment) by using a JNCL disease specific scoring system introduced by Kohlschütter et al. (1988). Scores were given for the problems of vision, intellect, language, motor function, as well as epilepsy, and compared with the data of 17 German JNCL patients not treated with antioxidants (Kohlschütter et al. 1988). Loss of vision began at the same time among the Finnish and the German JNCL patients. However, loss of intellectual, language, and motor functions and total blindness occurred later among the group of Finnish JNCL patients treated with antioxidants. Courses of the epileptic seizures were rather heterogenous and slightly favouring the Finnish patients. This study supports the theory that antioxidant treatment retards JNCL disease. The study design, however, contains many possible biases, so that the results must be interpreted cautiously.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2486154     DOI: 10.1007/978-1-4899-5339-1_19

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

Review 1.  Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Karen Berman; Henry Brodaty
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Clinical trials in rare disease: challenges and opportunities.

Authors:  Erika F Augustine; Heather R Adams; Jonathan W Mink
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

3.  [18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.

Authors:  H M Ruottinen; J O Rinne; M Haaparanta; O Solin; J Bergman; V J Oikonen; I Järvelä; P Santavuori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

4.  Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).

Authors:  Erika F Augustine; Christopher A Beck; Heather R Adams; Sara Defendorf; Amy Vierhile; Derek Timm; Jill M Weimer; Jonathan W Mink; Frederick J Marshall
Journal:  JIMD Rep       Date:  2018-06-20

5.  MRI of neuronal ceroid lipofuscinosis. I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis.

Authors:  T Autti; R Raininko; S L Vanhanen; P Santavuori
Journal:  Neuroradiology       Date:  1996-07       Impact factor: 2.804

Review 6.  [Neuroinflammation in neuronal ceroid lipofuscinosis].

Authors:  V Behnke; T Langmann
Journal:  Ophthalmologe       Date:  2021-01-07       Impact factor: 1.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.